Alicia K. Morgans, MD | Authors

Alicia Morgans, MD, MPH, on the Rationale for Examining the Clinical and Cost Impact of Cabazitaxel in mCRPC

October 11, 2021

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology Congress to talk about the rationale for analyzing the financial impact of cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.